Gene Editing Gets Public Market Approval as Calyxt Raises $64m IPO

Gene editing has caused a lot of excitement in agriculture technology circles for its potential to produce crops, and even animals, with improved characteristics. The technique, which enables undesirable traits — such as intolerance to heat — to be edited out of a genome,  or preferred traits — such as high nutritional content — to be enhanced, has also been lauded as a “non-GMO” method of advancing breeding; creating crops with characteristics that many argue would naturally appear over generations through evolution without the introduction of any foreign DNA.

With consumer acceptance of GMO food at all time lows, this technology could be a game changer for many sectors and last week the public markets got their first chance to access it in an agricultural context.

Calyxt, a Minnesota-based subsidiary of French biopharmaceutical company Cellectis, successfully spun out from its parent and raised $64.4 million in an IPO on the Nasdaq stock exchange. While pricing at the bottom of its $8-$10 a share range — revised down from an earlier $15-$18 range — the stock was a hit on its first day gaining 30% and reaching a high of $11.25. The offering was also oversubscribed, with the underwriters selling their optional over-allotment. It is currently trading around $10.70 with the ticker CLXT.

Read the full story at www.AgFunderNews.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s